Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7

Circulation Research

Volumn 108, Issue 2, 2011, Pages 164-175

  He, Xuyu ^a   Gao, Xiuren ^a   Peng, Longyun ^a   Wang, Shenming ^a   Zhu, Yingying ^a   Ma, Hong ^a   Lin, Jun ^b   Duan, Dayue Darrel ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin II; atrial fibrillation; atrial remodeling; Smads; transforming growth factor

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; HYDROXYPROLINE; LOSARTAN; PROTEIN KINASE INHIBITOR; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FAR WESTERN BLOTTING; FIBROBLAST; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATRIAL FIBRILLATION; CELLS, CULTURED; COLLAGEN; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FIBROSIS; LOSARTAN; MODELS, ANIMAL; MYOCARDIUM; RABBITS; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, SMALL INTERFERING; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN-PROTEIN LIGASES;

EID: 79451475323     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.234369     Document Type: Article

References (44)

1. Blaauw Y, Crijns HJ. Atrial fibrillation: insights from clinical trials and novel treatment options. J Intern Med. 2007;262:593-614.
2. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802-809.
3. Wyse DG, Gersh BJ. Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation. 2004;109:3089-3095.
4. Beyerbach DM, Zipes DP. Mortality as an endpoint in atrial fibrillation. Heart Rhythm. 2004;1:B8-B18.
5. Everett TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm. 2007;4:S24-S27.
6. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87-95.
7. Aldhoon B, Melenovsky V, Peichl P, Kautzner J. New insights into mechanisms of atrial fibrillation. Physiol Res. 2010;59:1-12.
8. Schroder D, Heger J, Piper HM, Euler G. Angiotensin II stimulates apoptosis via TGF-beta1 signaling in ventricular cardiomyocytes of rat. J Mol Med. 2006;84:975-983.
9. Boldt A, Scholl A, Garbade J, Resetar ME, Mohr FW, Gummert JF, Dhein S. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol. 2006; 101:261-267.
10. Hirayama Y, Atarashi H, Kobayashi Y, Takano T. Angiotensin-converting enzyme inhibitors are not effective at inhibiting further fibrous changes in the atria in patients with chronic atrial fibrillation: speculation from analysis of the time course of fibrillary wave amplitudes. Jpn Heart J. 2004;45:93-101.
11. Chrysostomakis SI, Karalis IK, Simantirakis EN, Koutsopoulos AV, Mavrakis HE, Chlouverakis GI, Vardas PE. Angiotensin II type 1 receptor inhibition is associated with reduced tachyarrhythmia-induced ventricular interstitial fibrosis in a goat atrial fibrillation model. Car-diovasc Drugs Ther. 2007;21:357-365.
12. Buxton IL, Duan D. Cyclic GMP/protein kinase G phosphorylation of Smad3 blocks transforming growth factor-beta-induced nuclear Smad translocation: a key antifibrogenic mechanism of atrial natriuretic peptide. Circ Res. 2008;102:151-153.
13. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8: 970-982.
14. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685-700.
15. Zhao J, Crowe DL, Castillo C, Wuenschell C, Chai Y, Warburton D. Smad7 is a TGF-beta-inducible attenuator of Smad2/3-mediated inhibition of embryonic lung morphogenesis. Mech Dev. 2000;93:71-81. (Pubitemid 30216497)
16. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation. 2005;111:2509-2517.
17. De Boer RA, Pokharel S, Flesch M, Van Kampen DA, Suurmeijer AJ, Boomsma F, Van Gilst WH, Van Veldhuisen DJ, Pinto YM. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR (mRen2)27. J Mol Med. 2004;82:678-687.
18. Moriguchi M, Niwano S, Yoshizawa N, Kitano Y, Kojima J, Inuo K, Saitou J, Izumi T. Inhomogeneity in the appearance of electrical remodeling during chronic rapid atrial pacing: evaluation of the dispersion of atrial effective refractoriness. Jpn Circ J. 2001;65:335-340.
19. Sheehan D, Hrapchak B. Theory and Practice of Histotechnology. Columbus, Ohio: Batelle Press; 1980.
20. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem. 1981;112:70-75.
21. Ju H, Hao J, Zhao S, Dixon IM. Antiproliferative and antifibrotic effects of mimosine on adult cardiac fibroblasts. Biochim Biophys Acta. 1998; 1448:51-60.
22. Peterson DJ, Ju H, Hao J, Panagia M, Chapman DC, Dixon IM. Expression of Gi-2 alpha and Gs alpha in myofibroblasts localized to the infarct scar in heart failure due to myocardial infarction. Cardiovasc Res. 1999;41:575-585.
23. Nakao A, Roijer E, Imamura T, Souchelnytskyi S, Stenman G, Heldin CH, ten Dijke P. Identification of Smad2, a human Mad-related protein in the transforming growth factor beta signaling pathway. J Biol Chem. 1997;272:2896-2900.
24. Britton FC, Wang GL, Huang ZM, Ye L, Horowitz B, Hume JR, Duan D. Functional characterization of novel alternatively spliced ClC-2 chloride channel variants in the heart. J Biol Chem. 2005;280:25871-25880.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
26. Hill-Kapturczak N, Truong L, Thamilselvan V, Visner GA, Nick HS, Agarwal A. Smad7-dependent regulation of heme oxygenase-1 by transforming growth factor-beta in human renal epithelial cells. J Biol Chem. 2000;275:40904-40909.
27. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
28. Wang DH, Yao A, Zhao H, DiPette DJ. Regulation of ANG II receptor in hypertension: role of ANG II. Am J Physiol. 1996;271:H120-H125.
29. Cunnington RH, Nazari M, Dixon IM. c-Ski, Smurf2, and Arkadia as regulators of TGF-beta signaling: new targets for managing myofi-broblast function and cardiac fibrosis. Can J Physiol Pharmacol. 2009; 87:764-772.
30. Laurent G, Moe GW, Hu X, Pui-Sze SP, Ramadeen A, Leong-Poi H, Doumanovskaia L, Konig A, Trogadis J, Courtman D, Strauss BH, Dorian P. Simultaneous right atrioventricular pacing: a novel model to study atrial remodeling and fibrillation in the setting of heart failure. J Card Fail. 2008;14:254-262.
31. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184.
32. Shirani J, Alaeddini J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesoph-ageal echocardiography. Cardiovasc Pathol. 2000;9:95-101.
33. Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med. 2008;12:189-208.
34. Fukaya H, Niwano S, Satoh D, Masaki Y, Niwano H, Kojima J, Moriguchi M, Izumi T. Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model. Circ J. 2008;72: 318-326. (Pubitemid 351413375)
35. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002;91:1103-1113.
36. Nakajima H, Nakajima HO, Salcher O, Dittie AS, Dembowsky K, Jing S, Field LJ. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res. 2000;86:571-579.
37. Nakashima H, Kumagai K. Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J. 2007;71: 1977-1982.
38. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947-1958.
39. Sun Y, Zhang JQ, Zhang J, Ramires FJ. Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol. 1998;30:1559-1569.
40. Seko Y, Nishimura H, Takahashi N, Ashida T, Nagai R. Serum levels of vascular endothelial growth factor and transforming growth factor-beta1 in patients with atrial fibrillation undergoing defibrillation therapy. Jpn Heart J. 2000;41:27-32.
41. Barth AS, Merk S, Arnoldi E, Zwermann L, Kloos P, Gebauer M, Steinmeyer K, Bleich M, Kaab S, Hinterseer M, Kartmann H, Kreuzer E, Dugas M, Steinbeck G, Nabauer M. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res. 2005;96:1022-1029.
42. Cardin S, Libby E, Pelletier P, Le BS, Shiroshita-Takeshita A, Le MN, Leger J, Demolombe S, Ponton A, Glass L, Nattel S. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ Res. 2007;100:425-433.
43. Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res. 2004;95:1167-1173.
44. Halder SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res. 2005;307:231-246.